GLP-1R agonists are known for the treatment of type 2 diabetes, but have also been shown to be cardio-protective in preclinical and clinical studies by reducing myocardial infarct size and improving ventricular function after ischemia (Noyan-Ashraf et al., 2009; Lonborg et al., 2012; Read et al., 2012). Here, GLP1R is linked to myocardial infarction.